US Pharma MarketingThe post Ipsen reports sustained duration of effect in Phase II corabotase trial appeared first on Clinical Trials Arena.
Ipsen reports sustained duration of effect in Phase II corabotase trial
Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction. The 50ng dose of corabotase will undergo further evaluation in the Phase III LAURITE programme. Patient-reported data showed corabotase (50ng) acted in 0.84 days, with safety profile similar to Dysport and placebo. Credit: THICHA SATAPITANON / Shutterstock.com. Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction. The first clinical results involving 183 patients for its recombinant neuroinhibitor were shared during the 2026 Scale Symposium in Nashville, Tennessee, US, focusing…
Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction.
Source: Clinical Trials Arena